Kyowa Kirin Co., Ltd.
Otemachi Financial City Grand Cube
1-9-2, Otemachi Chiyoda-ku
Tokyo 100-0004
Japan
81 3 5205 7200
https://www.kyowakirin.com
版塊: Healthcare
行業: Drug Manufacturers - General
全職員工: 5,974
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Masashi Miyamoto Ph.D. | President, CEO & Representative Director | 128M | 無 | 1959 |
| Mr. Motohiko Kawaguchi | CFO & Managing Executive Officer | 無 | 無 | 無 |
| Mr. Yutaka Osawa M.B.A. | CCO, Executive VP & Representative Director | 78M | 無 | 1959 |
| Kazuki Nemoto | Head of Global Legal | 無 | 無 | 無 |
| Hiroki Nakamura | Global Corporate Communications Head | 無 | 無 | 無 |
| Hiroshi Sonekawa | Managing Executive Officer, VP and Head of Sales & Marketing Division | 無 | 無 | 無 |
| Mr. Takeyoshi Yamashita Ph.D. | Chief Medical Officer, Senior Managing Executive Officer & Director | 無 | 無 | 1961 |
| Yasuo Fujii M.B.A. | Chief Strategy Officer, VP & Managing Executive Officer | 無 | 無 | 無 |
| Jean-David Rafizadeh-Kabe J.D., M.D. | Head of Global Operational Transformation | 無 | 無 | 無 |
| Yoshifumi Torii Ph.D. | Executive Officer & Head of Global Research | 無 | 無 | 無 |
描述
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; and Romiplate/Nplate, a genetically recombinant protein that produces platelet through the stimulation of thrombopoietin receptors. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, an anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
公司管治
截至 2024年6月29日 止，Kyowa Kirin Co., Ltd. 的 ISS 管治質素評分為 1。 Pillar 分數正在審核中：1；董事會：1；股東權利：2；現金賠償：1。
